Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Lung Cancer and Personalized Medicine
share announcement

Lung Cancer and Personalized Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 11849

Special Issue Editor

Dr. Christos Damaskos

E-Mail Website
Guest Editor
Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
Interests: surgery; transplantation; surgical oncology; oncology; experimental surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer is the leading cause of cancer death worldwide, with more than 1 million deaths annually. It is classified into multiple histological subtypes. How similar are these subtypes in genetic background and prognosis, however? Despite recent advances in diagnostic and therapeutic strategies, the prognosis of several subtypes of lung cancer remains poor. This Special Issue aims to clarify the characteristics between the subtypes of lung cancer and their associations with prognosis and therapy.

Dr. Christos Damaskos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Lung cancer
  • Histopathology
  • Characteristics
  • Prognosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

27 pages, 10002 KiB  
Review
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
by Maja Šutić, Ana Vukić, Jurica Baranašić, Asta Försti, Feđa Džubur, Miroslav Samaržija, Marko Jakopović, Luka Brčić and Jelena Knežević
J. Pers. Med. 2021, 11(11), 1102; https://0-doi-org.brum.beds.ac.uk/10.3390/jpm11111102 - 27 Oct 2021
Cited by 40 | Viewed by 8974
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved [...] Read more.
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the “one-fits-all” paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer. Full article
(This article belongs to the Special Issue Lung Cancer and Personalized Medicine)
►▼ Show Figures

Figure 1

Other

Jump to: Review

9 pages, 5918 KiB  
Case Report
Tumour Genome Characterization of a Rare Case of Pulmonary Enteric Adenocarcinoma and Prior Colon Adenocarcinoma
by Robert J. Smyth, Valentina Thomas, Joanna Fay, Ronan Ryan, Siobhan Nicholson, Ross K. Morgan, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Sinead Toomey, Bryan T. Hennessy and Simon J. Furney
J. Pers. Med. 2021, 11(8), 768; https://0-doi-org.brum.beds.ac.uk/10.3390/jpm11080768 - 04 Aug 2021
Cited by 2 | Viewed by 2012
Abstract
Pulmonary enteric adenocarcinoma (PEAC) is a rare variant of lung adenocarcinoma first described in the early 1990s in a lung tumour with overlapping lung and small intestine features. It is a rare tumour with fewer than 300 cases described in the published literature [...] Read more.
Pulmonary enteric adenocarcinoma (PEAC) is a rare variant of lung adenocarcinoma first described in the early 1990s in a lung tumour with overlapping lung and small intestine features. It is a rare tumour with fewer than 300 cases described in the published literature and was only formally classified in 2011. Given these characteristics the diagnosis is challenging, but even more so in a patient with prior gastrointestinal malignancy. A 68-year-old Caucasian female presented with a cough and was found to have a right upper lobe mass. Her history was significant for a pT3N1 colon adenocarcinoma. The resected lung tumour showed invasive lung adenocarcinoma but also features of colorectal origin. Immuno-stains were strongly and diffusely positive for lung and enteric markers. Multi-region, whole-exome sequencing of the mass and archival tissue from the prior colorectal cancer showed distinct genomic signatures with higher mutational burden in the PEAC and very minimal overlap in mutations between the two tumours. This case highlights the challenge of diagnosing rare lung tumours, but more specifically PEAC in a patient with prior gastro-intestinal cancer. Our use of multi-region, next-generation sequencing revealed distinct genomic signatures between the two tumours further supporting our diagnosis, and evidence of PEAC intra-tumour heterogeneity. Full article
(This article belongs to the Special Issue Lung Cancer and Personalized Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop